The investor presentation “MagSense® Technology: A New Diagnostic for Targeted Early Detection of Cancer” was presented at the 2017 Annual General Meeting. View the Investor Presentation.
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December
December 2, 2025
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December Key Highlights: MagSense® HER2